Angiogenesis, the growth of new blood vessels, is at the origin of many diseases affecting more than one billion people worldwide. Conditions affected by angiogenesis include blindness, cancers, cardiovascular disease, complications of diabetes, arthritis, and more.1
Gene Signal is a research and development based biotechnology company focused on discovering genes involved in the regulation of angiogenesis. Gene Signal is currently developing therapeutic solutions based on a family of antisense oligonucleotides (short DNA fragments) to conquer disease associated with significant unmet medical needs despite the advent of VEGF (Vascular Endothelial Growth Factor) based therapies.
Gene Signal is currently completing recruitment for its Phase III study for GS-101 (Aganirsen), its most advanced therapeutic ophthalmic solution. Gene Signal is also evaluating three other drugs in ophthalmology and in dermatology and is in the discovery phase with four more molecules addressing indications in the field of vascular disease and oncology. Seven more R&D products are in the pipeline.
Gene Signal’s discovery program leverages a patented gene discovery platform named GENE-MAAP (GENE Signal Angiogeneis, Angiostatic Platform). GENE-MAAP streamlines the identification process of genes exclusively involved in the regulation of angiogenesis and has allowed Gene Signal to identify and patent more than 94 genes involved in the angiogenic process.
